S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Meeting Abstract

    Heinemann, V.; Bekaii-Saab, T.; Van Cutsem, E.; Tabernero, J.; Siena, S.; Yoshino, T.; Nakamura, Y.; Raghav, K.; Cercek, A.; Adelberg, D.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • A phase I study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9
    Meeting Abstract

    Leypoldt, L.; Usmani, S. Z.; Mielnik, M.; Byun, J. M.; Alonso, A.; Abdallah, A. O.; Garg, M.; Quach, H.; Min, C. K.; Janowski, W.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Meeting Abstract

    Moehler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW
    Meeting Abstract

    Lordick, F.; Xu, R. H.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Galle, P. R.; Crysler, O.; Yarchoan, M.; Furuse, J.; Sukeepaisarnjaroen, W.; Thinh, N. T.; Masi, G.; Lim, H. Y.; Varela, M.; Gupta, C.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (Pts) with claudin-18.2+(CLDN18.2+) / HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
    Meeting Abstract

    Lordick, F.; Shitara, K.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion Cancer
    Meeting Abstract

    Rieke, D. T.; Hong, D. S.; Drilon, A.; Tan, D. S.; Lin, J.; Kummar, S.; McDermott, R.; Berlin, J.; Italiano, A.; Lassen, U. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)
    Meeting Abstract

    Tesch, H.; Tolaney, S.; Bardia, A.; Marmé, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tréedan, O.; Ciruelos, E.; Dalenc, F.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia
    Meeting Abstract

    Christofyllakis, K.; Roeker, L.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save